How well do you know the regulatory requirements regarding the assessment of endocrine disrupting potential of active substances? In this webinar, the first of a three-part series, regulatory consultant Ira Koval will explain updates to PPP Regulation (Regulation (EC) 1107/2009) and BPR (Regulation (EU) 528/2012).
Bring your questions and prepare to learn something new as we dive into templates, data requirements, the evaluation of co-formulants, and assessing the impact on non-target organisms. We will also share insights into other relevant issues, such as investigation of the mode of action, when and which new data are expected to be generated and whether the opportunities exist to demonstrate negligible exposure.
Ira Koval, PhD
Section Head of Global Regulatory Consultancy
View the other webinars in the series:
- In Vitro Assessment of Endocrine Disruptors: Insights & Developments (June 11)
- In Vivo ED Testing: Practical Approaches for Rodents and Aquatic Vertebrate Studies (June 18)
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
During this time of uncertainty, we are focused on providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.